3,4-diethyl aniline | 54675-14-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3,4-diethyl aniline
• 英文别名: 3,4-diethylaniline；3,4-diethyl-aniline；3,4-Diaethyl-anilin
• CAS: 54675-14-8
• 化学式: C₁₀H₁₅N
• mdl: MFCD18971287
• 分子量: 149.236
• InChiKey: JAKHLQNEMUMGKP-UHFFFAOYSA-N

物化性质

• 沸点：
  146 °C(Press: 13 Torr)
• 密度：
  0.948±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2921420090

反应信息

• 作为反应物：
  描述：

  3,4-diethyl aniline 在 sodium hydroxide 、 丙酮 作用下， 生成 4,5-二乙基-2-硝基苯胺
  参考文献：
  名称：

  Synthesis of 2,5-Dihydroxyphenylalanine

  摘要：

  DOI：

  10.1021/ja01179a051
• 作为产物：
  描述：

  3,4-divinyl-aniline 在 乙醇 、 铂 作用下， 生成 3,4-diethyl aniline
  参考文献：
  名称：

  Fries; Bestian, Justus Liebigs Annalen der Chemie, 1938, vol. 533, p. 72,83

  摘要：

  DOI：

文献信息

• PYRIMIDINE-2,4-DIAMINE DERIVATIVES AND THEIR USE AS JAK2 KINASE INHIBITORS
  申请人：Vankayalapati Hariprasad

  公开号：US20080214558A1

  公开（公告）日：2008-09-04

  Pyrimidine-2,4-diamines derivatives having activity as JAK2 kinase inhibitors are disclosed, as well as pharmaceutical compositions and methods for using the same in the treatment of cancer and other JAK2 kinase-associated conditions.

  翻译结果为：披露了具有JAK2激酶抑制活性的嘧啶-2,4-二胺衍生物，以及用于治疗癌症和其他与JAK2激酶相关的条件的药物组合物和方法。
• [EN] NOVEL COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS<br/>[FR] NOUVEAUX COMPOSÉS POUR LE TRAITEMENT DE MALADIES ASSOCIÉES AUX PROTÉINES AMYLOÏDES OU DE TYPE AMYLOÏDE
  申请人：AC IMMUNE SA

  公开号：WO2011128455A1

  公开（公告）日：2011-10-20

  The present invention relates to novel compounds that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein, such as Alzheimer's disease, and of diseases or conditions associated with amyloid-like proteins. The compounds of the present invention can also be used in the treatment of ocular diseases associated with pathological abnormalities/changes in the tissues of the visual system. The present invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the preparation of medicaments for treating or preventing diseases or conditions associated with amyloid and/or amyloid-like proteins. A method of treating or preventing diseases or conditions associated with amyloid and/or amyloid-like proteins is also disclosed.

  本发明涉及一类新化合物，可用于治疗与淀粉样蛋白相关的一组疾病和异常，例如阿尔茨海默病，以及与类淀粉样蛋白相关的疾病或状况。本发明的化合物还可用于治疗与视觉系统组织病理性异常/变化相关的眼病。本发明还涉及包含这些化合物的药物组合物，以及使用这些化合物制备用于治疗或预防与淀粉样和/或类淀粉样蛋白相关的疾病或状况的药物。还公开了一种治疗或预防与淀粉样和/或类淀粉样蛋白相关疾病或状况的方法。
• ACETYLENE COMPOUND, SALT THEREOF, CONDENSATE THEREOF, AND COMPOSITION THEREOF
  申请人：Fujifilm Corporation

  公开号：EP2202220A1

  公开（公告）日：2010-06-30

  [Problem to be Solved] To provide an acetylene compound having a structure in which a unit having an amino group and a unit having an ethynyl group are bonded via a linking group, the acetylene compound being introducable to a polymer having thermal resistance. [Means for Solving the Problem] An acetylene compound represented by the following Formula (1) and a salt thereof: wherein in Formula (1), X represents a single bond or a divalent linking group; A represents a hydrocarbon group, a heteroaromatic ring or a heteroalicyclic compound; B represents a hydrocarbon group, a heteroaromatic ring, a heteroalicyclic compound or a single bond; R1 represents a hydrogen atom, a hydrocarbon group, a heteroaromatic ring, a heteroalicyclic compound or a silyl group; R4 represents a hydrogen atom or a group that can be a substituent of an amino group; and m, n and a each independently represent an integer of 1 or greater.

  解决的问题是提供一种乙炔化合物，其结构中含有通过连接基团连接的具有氨基团和乙炔基团的单元，该乙炔化合物可引入到具有热阻抗的聚合物中。解决问题的方法是通过以下式（1）表示的乙炔化合物及其盐：其中在式（1）中，X代表单键或二价连接基团；A代表烃基团、杂环芳香环或杂环脂环化合物；B代表烃基团、杂环芳香环、杂环脂环化合物或单键；R1代表氢原子、烃基团、杂环芳香环、杂环脂环化合物或硅基团；R4代表氢原子或可作为氨基团的取代基团；m、n和a分别独立表示大于或等于1的整数。
• Specific inhibitor of puromycin-sensitive aminopeptidase with a homophthalimide skeleton: identification of the target molecule and a structure–activity relationship study
  作者：Masato Komoda、Hiroki Kakuta、Hiroyasu Takahashi、Yasuyuki Fujimoto、Shizuo Kadoya、Fuminori Kato、Yuichi Hashimoto

  DOI：10.1016/s0968-0896(00)00231-5

  日期：2001.1

  ,3-dione (2: PIQ-22) was found to be a potent and specific inhibitor of puromycin-sensitive aminopeptidase (PSA). Lineweaver-Burk plot analysis showed that PSA is inhibited by PIQ-22 in a non-competitive manner. Structure -activity relationship studies indicated that tautomerism of the imidobenzoylketone group in the cyclic imide moiety of the PIQ-22 skeleton is important for the inhibitory activity

  发现2-（2，6-二乙基苯基）-1，2，3，4-四氢异喹啉-1，3-二酮（2：PIQ-22）是嘌呤霉素敏感性氨基肽酶（PSA）的有效和特异性抑制剂。Lineweaver-Burk图分析表明，PSA被PIQ-22抑制为非竞争性方式。结构-活性关系研究表明，PIQ-22骨架的环状酰亚胺部分中的亚氨基苯甲酰基酮基的互变异构对于抑制活性很重要。
• Pyrimidine-2, 4-diamine JAK2 Kinase inhibiting anti-inflammation use
  申请人：Hwang Soo-In

  公开号：US20100029675A1

  公开（公告）日：2010-02-04

  A method of treatment or prevention of Castleman's disease, atherosclerosis, coronary artery disease, peripheral edema, peripheral vascular disease, glaucoma, and wet or dry age-related macular degeneration (AMD), asthma; chronic bronchitis; chronic obstructive pulmonary disease; adult respiratory distress syndrome; infant respiratory distress syndrome; cough; chronic obstructive pulmonary disease in animals; adult respiratory distress syndrome; ulcerative colitis; Crohn's disease; hypersecretion of gastric acid; bacterial, fungal, or viral induced sepsis or septic shock; endotoxic shock; laminitis or colic in horses; spinal cord trauma; head injury; neurogenic inflammation; pain; reperfusion injury of the brain; psoriatic arthritis; rheumatoid arthritis; alkylosing spondylitis; osteoarthritis; inflammation; or cytokine-mediated chronic tissue degeneration comprises the step of administering a therapeutically effective amount, or a prophylactically effective amount, of a compound having the following structure (I):

  一种治疗或预防卡斯尔曼病、动脉粥样硬化、冠状动脉疾病、周围水肿、周围血管疾病、青光眼、湿性或干性老年性黄斑变性（AMD）、哮喘；慢性支气管炎；慢性阻塞性肺病；成人呼吸窘迫综合征；婴儿呼吸窘迫综合征；咳嗽；动物的慢性阻塞性肺病；成人呼吸窘迫综合征；溃疡性结肠炎；克罗恩病；胃酸过分分泌；细菌、真菌或病毒诱导的败血症或感染性休克；内毒素性休克；马的蹄叶炎或肠绞痛；脊髓创伤；头部损伤；神经源性炎症；疼痛；脑再灌注损伤；银屑病性关节炎；类风湿性关节炎；强直性脊柱炎；骨关节炎；炎症；或细胞因子介导的慢性组织退化的治疗方法包括给予具有以下结构（I）的化合物的治疗有效量或预防有效量。